利妥昔单抗治疗儿童难治性慢性特发性血小板减少性紫癜9例近期疗效

摘要

Objective To investigate the therapeutic effect of rituximab in the treatment of 9 patients with chronic refractory immune thrombocytopenic purpura (ITP) in children. Methods Nine cases were treated in our hospital from 2008 to 2010. All patients received rituximab 100 mg per week intravenously for 4 consecutive weeks. Therapeutic effect and side effect of the rituximab regimen were observed. Results The response time took 1 ～6 weeks with an effective rate of 67％ and a relapse rate of 33％. Two splenectomized patients had no response. Conclusion Rituximab could induce a clinically significant response in childhood chronic refractory ITP with a rapid response and little toxicity, but with a relapse tendency.%目的 观察利妥昔单抗治疗儿童难治性慢性特发性血小板减少性紫癜(ITP)的近期疗效.方法 选择我院2008年6月-2010年6月期间确诊为难治性、慢性ITP患儿9例,给予利妥昔单抗100 mg静脉滴注,每周1次,连用4周.结果治疗起效时间1～6周,有效率为67%,复发率为33%,2例切脾患儿无效.结论 利妥昔单抗治疗儿童难治性、慢性ITP起效快、缓解率较高、毒副作用小,但有复发倾向.